Sakar Healthcare Limited — PPTs, 28-07-2026: Investor Presentation

Sakar Healthcare delivered strong Q1FY27 results, with revenue jumping 38% YoY to ₹72.97 Cr, fueled by new oncology product authorizations and robust demand. Profit After Tax (PAT) surged 120% YoY to ₹10.28 Cr, with Basic EPS at ₹4.62. EBITDA grew 67% YoY to ₹21.25 Cr, achieving 29% margins.

The company's strategy focuses on an integrated, regulatory-driven oncology business, enhancing its value chain and operational efficiency. Recent milestones include 65+ oncology product contracts, 16 global Marketing Authorizations, and 21 APIs developed in-house. A key partnership with Zydus Lifesciences boosts its anti-cancer product reach.

Management attributes improved profitability to operating leverage and efficiency gains. Sakar aims for significant growth, targeting over 100 overseas business contracts and 300+ dossier approvals in the next two years, solidifying its "Oncology at the Core" growth plan.